Clinical trial
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
NCT00191035 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191035 |
|---|---|
| Title | Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD |
| Official title | Maintenance of Benefit After 8-Week and 52-Week Treatment With Atomoxetine Hydrochloride in Adolescents With ADHD |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Attention-Deficit/Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine |
| Enrollment | 520 |
| Start date | Mar 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 13, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: